Skip to content

Physical Activity on Neuroinflammation in Parkinson's Disease

Role of Physical Activity on Neuroinflammation in Parkinson's Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06977204
Acronym
MOVE-ON_WP1
Enrollment
40
Registered
2025-05-18
Start date
2023-01-01
Completion date
2026-06-01
Last updated
2025-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease, Physical Disability, Physical Inactivity

Keywords

Physical activity, Neurological disorder, Neuroinflammation

Brief summary

Parkinson's Disease (PD) is a chronic progressive neurodegenerative disorder clinically defined by the association of resting tremor, rigidity, bradykinesia, and postural instability. The histopathology of PD is characterized by the loss of neurons in the substantia nigra pars compacta (SNPc) and the accumulation of α-synuclein aggregates within Lewy bodies. The pathogenic mechanisms underlying the development of the disease, however, are not yet fully understood: genetics, cellular oxidative stress, mitochondrial dysfunction, environmental factors, and neuroinflammation are all potential mechanisms involved in the pathogenesis of PD. Several studies have now established the involvement of neuroinflammation in the pathogenesis of PD. It is known that α-synuclein aggregates stimulate microglia and astroglia to secrete pro-inflammatory mediators such as IL 1β, IL6, and TNFα. These molecules activate an inflammatory response characterized by altered blood-brain barrier permeability, leukocyte recruitment, and the expression of other pro-inflammatory cytokines. These events contribute to exposing neurons to oxidative stress and cellular damage. Additionally, cellular damage induces neurons to stimulate the release of DAMPs (Damage Associated Molecular Patterns), which in turn activate glial cells. This creates a state of chronic inflammation that could play a role in the progression of the disease. Supporting this hypothesis, elevated levels of IL1β, IL6, and TNFα have been found in the striatum and SNPc of post-mortem PD samples. The transcription factor Nrf2 is one of the main regulators of cellular protection in response to stress (inflammation, redox, xenobiotics). Nrf2 promotes the expression of several genes that cooperate in a cytoprotective response, which includes antioxidant defense, resolution of inflammation, increased mitochondrial activity, and protein turnover. Recent clinical studies seem to confirm the hypothesis that Nrf2 plays a role in the pathogenesis of PD, as already suggested by preclinical models. Specifically, altered plasma levels of the Nrf2-activated pathway have been observed in preclinical models. Studies conducted on animal models of PD have hypothesized how exercise might correlate with protective mechanisms and might promote neuroplasticity and neuro-regeneration, especially when practiced at high intensity. Physical exercise can indeed modulate various systems (including inflammatory pathways and oxidative stress) that regulate neuroinflammation and glial activation. However, the available results are not definitive and often focus on single and separate aspects of the disease. The aim of the study is to investigate the beneficial effect of physical exercise in patients with Parkinson's Disease (PD). Literature already suggests an improvement in various domains of motor and non-motor aspects, as well as in the overall quality of life, of PD patients even after a period of aerobic activity. Generally, training periods included 3-4 sessions per week of 40-60 minutes each for 4-16 weeks. In general, the literature describes the effects of moderate physical training, while little or nothing is known about how PD is affected by high-intensity sports training. The primary objective of our study is to compare a group of PD patients undergoing regular and constant intense exercise (PD-sport) with a control group consisting of PD patients leading a sedentary life (PD-sedentary). The primary outcome will be the difference in systemic inflammatory status between the PD-sport group and the PD-sedentary group.

Detailed description

Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder clinically defined by the presence of resting tremor, rigidity, bradykinesia, and postural instability. Pathologically, PD is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein aggregates within Lewy bodies. While the precise pathogenic mechanisms underlying PD remain incompletely understood, evidence suggests a multifactorial etiology involving genetic predisposition, oxidative stress, mitochondrial dysfunction, environmental factors, and neuroinflammation. Emerging research highlights the pivotal role of neuroinflammation in PD pathogenesis. α-Synuclein aggregates are known to activate microglia and astroglia, triggering the release of pro-inflammatory mediators such as IL-1β, IL-6, and TNF-α. This inflammatory response disrupts blood-brain barrier integrity, recruits leukocytes, and amplifies the production of other pro-inflammatory cytokines, exposing neurons to oxidative stress and cellular damage. In turn, neuronal damage promotes the release of damage-associated molecular patterns (DAMPs), perpetuating chronic inflammation. Elevated levels of IL-1β, IL-6, and TNF-α have been detected in the striatum and SNpc of post-mortem PD samples, underscoring the role of inflammation in disease progression. The transcription factor Nrf2 is a master regulator of cellular defense mechanisms against oxidative and inflammatory stress. Nrf2 orchestrates the expression of genes involved in antioxidant defense, inflammation resolution, mitochondrial activity, and protein turnover. Clinical and preclinical studies suggest that dysregulation of the Nrf2 pathway may contribute to PD pathogenesis, as evidenced by altered plasma levels of Nrf2-regulated pathways in preclinical PD models. Animal studies have proposed that physical exercise may confer neuroprotective effects by promoting neuroplasticity and neuro-regeneration, particularly through high-intensity training. Exercise has been shown to modulate inflammatory pathways, reduce oxidative stress, and influence glial activation. Despite promising results, most studies have focused on isolated aspects, leaving gaps in our understanding of the comprehensive effects of exercise on PD. This study aims to investigate the beneficial effects of adapted physical exercise in patients with PD, focusing on its impact on systemic inflammation and secondary outcomes such as gait parameters, functional markers of exercise tolerance, and quality of life. Study Design * Observational, case-control, study comparing regular and intense exercise (PD-sport) to a sedentary lifestyle (PD-sedentary). Primary objective: Evaluate differences in systemic inflammatory status between PD-sport and PD-sedentary groups. Secondary and Exploratory objective * Pro- and anti-inflammatory cytokines (IL-6, IL-10, IL-1β, IL-4, IL-17a, TNF-α). * Plasma extracellular vesicle (EV) profiles (number, size). * Gait parameters using inertial gait analysis. * Clinical tests (e.g., MET, 6MWT, UPDRS) and exercise tolerance biomarkers (e.g., VO2peak, gas exchange threshold). * Psychological outcomes (depression, quality of life, and pain scales). * Non-motor symptoms (NMS) and cognitive domain assessments. Recruitment Participants will be recruited at the IRCCS Mondino Foundation of Pavia, and patient associations. The study will enroll two groups: 1. PD-sport group: Individuals engaging in moderate-to-high-intensity physical activity. 2. PD-sedentary group: Individuals with a sedentary lifestyle. Physical activity levels will be assessed using the short version of the International Physical Activity Questionnaire (IPAQ). Evaluation Assessments will include: Comprehensive clinical evaluation by a movement disorder specialist. Biochemical analysis of inflammatory markers from fasting blood samples (35 mL). Gait analysis using the G-Walk system. Cognitive and psychological evaluations. Exercise tolerance indices measured via cardiopulmonary exercise testing.

Interventions

None listed

Sponsors

IRCCS National Neurological Institute C. Mondino Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subjects of both sexes, aged between 40 and 80 years (extremes included) * Diagnosis of Parkinson's disease according to the clinical diagnostic criteria of the Movement Disorder Society * Hoehn & Yahr between 1 and 3

Exclusion criteria

* Concomitant diagnosis of other neurological diseases * Presence of confirmed cognitive decline (MMSE \< 24) * Presence of depression with (BDI \> 40) * Patients with deep brain stimulation implant or undergoing DuoDopa therapy * Presence of significant diseases affecting the musculoskeletal system * Presence of internal medicine conditions, considered clinically significant by the investigator * Acute or recent infections * Body Mass Index (BMI) \>= 30 * Active smoking behavior * Ongoing treatment with N-acetylcysteine or anti-oxidants * Pregnancy or lactation

Design outcomes

Primary

MeasureTime frameDescription
Set of serum pro-inflammatory and anti-inflammatory cytokinesSingle evaluation at baselinethe investigators will dose a set of of pro-inflammatory and anti-inflammatory cytokines in the serum, namely interleukin 1β (IL-1β), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 (IL-12), tumor necrosis factor alpha (TNF-alpha), and interferon (IFN).

Secondary

MeasureTime frameDescription
Time Up and Go testSingle evaluation at baselineTime Up and Go test (continuous variable with units of measurement: second)
Inertial Gait AnalysisSingle evaluation at baselineGait analysis performed Inertial Measeurement Units to assess spatio-temporal variables ( continuous variables: m/s)
5 Sit to Stand TestSingle evaluation at baselineSit to Stand Test (continuous variable with units of measurement: second)
Hand Grip TestSingle evaluation at baselineHand Grip Test (continuous variable with units of measurement: N)
Incremental Maximal TestSingle evaluation at baselinePeak oxygen consumption (continuous variable with units of measurement: ml/kg/min)
The Parkinson's Disease Questionnaire PDQ-39Single evaluation at baselineParkinson's Disease Questionnaire (continuous variable, score ranging from 0 to 156 with higher scores indicating more severe disability)
Geriatric depression scale-30Single evaluation at baselineGeriatric depression scale-30 (continuous variable, score ranging from 0 to 30 with higher scores indicating more severe depression)
King's PD pain scale (KPPS)Single evaluation at baselineKing's PD pain scale (KPPS) (continuous variable, score ranging from 0 to 168 with higher scores indicating more severe pain)
Pain DetectSingle evaluation at baselinePain Detect (continuous variable, score ranging from -1 to 38 with higher scores indicating a more probable neurotic pain)
Peak work rateSingle evaluation at baselinePeak work rate (continuous variable with units of measuremente: w)
Peak heart rateSingle evaluation at baselinePeak heart rate (continuous variable with units of measuremente: b/min)
Gas exchange thresholdSingle evaluation at baselineGas exchange threshold (continuous variable with units of measuremente: l/min)
Brief Pain Inventory (BPI)Single evaluation at baselineBrief Pain Inventory (BPI) (continuous variable, score ranging from 0 to 10 with higher scores indicating more severe disability)

Countries

Italy

Contacts

Primary ContactRoberto De Icco
roberto.deicco@mondino.it+390382380425
Backup ContactCinzia Fattore
cinzia.fattore@mondino.it+390382380385

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026